1 DRUG DATABASE AND PERFORMANCE INDICATORS FOR UTILIZATION MONITORING Authors: Pongcharoensuk P 1, Angsanant M 2, Chantrakunopars P 2, Phuthong P 1, Kongsawat.

Slides:



Advertisements
Similar presentations
Medicines Prices and Methods of Financing in South-East Asia Indian Pharmacological Society 38 th Annual Conference, Chennai 29th December 2005 Dr K Weerasuriya,
Advertisements

“a mechanism for the collection, processing, analysis and transmission of information required for organizing and operating health services, and also for.
Differences in the availability of medicines used for chronic and acute conditions in developing countries Alexandra Cameron International Conference on.
Data-Driven Policy Decisions: Uses of Minnesota Hospital Data Julie Sonier Director, Health Economics Program Minnesota Department of Health December 4,
ECONOMIC ASSESSMENT OF IMPLEMENTATION TREATMENT GUIDELINES OF HYPERTENSION IN OUT-PATIENT PRACTICE Kulmagambetov IR Karaganda State Medical Academy, Kazakhstan.
Inthira Kanchanaphibool Faculty of Pharmacy, Silpakorn University, Thailand 1.
1. Health Policy Research Group Department of Pharmacology & Therapeutics, College of Medicine, University of Nigeria Enugu Campus 2. Department of Clinical.
Assessing the impact of a policy on universal coverage on financial risk protection, health care finance, and benefit incidence of the Thai health care.
Selection of Data Sources for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Application of an International Reference Price List to National Medicines Procurement Tenders Bada Pharasi, Gavin Steel, Jean-Pierre Sallet, SPS, Management.
1 Drug and Therapeutics Committee. Objectives  Discuss the use of aggregate data including defined daily dose in analyzing the consumption of medicines.
EDM STRATEGY FOR WORKING WITH COUNTRIES-TANZANIA Rose Shija EDM NPO TANZANIA.
Sakthivel Selvaraj, Habib Hasan Public Health Foundation of India, India 1.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Impact on prescribing patterns of a fee per drug unit versus a fee per drug item Kathleen Holloway 1, Karkee SB 2, Tamang AL 2, Gurung YB 2, Pradhan R.
Inputs, Outputs and Outcomes: What Measures, What Matters Glenda Yeates, President & CEO Canadian Institute for Health Information October 30, 2007.
Using Longitudinal Data for Evaluating Policy Changes and Other Interventions -Information system in Tamilnadu Medical Services Corporation.
The Pharmaceutical Situational Analysis in Mongolia 1 Chimedtseren Munkhdelger 1 Sanjjav Tsetsegmaa 2, 1 Ministry of Health, 2 Pharmacy School, Health.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
1 Institute for Population and Social Research (IPSR) FACTORS AFFECTING HEALTHCARE EXPENDITURE OF THE THAI ELDERLY Danusorn Potharin 1 and Wathinee Boonchalaksi.
Corticosteroid dosing in the treatment of acute exacerbations of COPD Kurt A. Wargo, Pharm.D., BCPS, Takova D. Wallace, Pharm.D. Candidate 2014, Ryan E.
PRICE SURVEY HIGHLIGHTS FOR STAKEHOLDERS MEETING 16-December, 2008.
Dr. David Mowat June 22, 2005 Federal, Provincial & Local Roles Surveillance of Risk Factors and Determinants of Chronic Diseases.
Scoring System for the Development of the National List of Essential Drugs in Thailand.
Drug Policy Experience of Visegrad Group countries, Warszava Oct 29-30, 2007 System of counting of reimbursement costs in the Czech Republic Tomas Sechser.
EFFECT OF PRIVATIZATION OF GENERAL MEDICAL STORE ON PRICES OF ANTI-INFECTIVES IN MALAYSIA Baber ZU 1, Ibrahim M 2, Bukhari NI 1 1 University College Sedaya.
Objective the aim of this project was directly addressing a major health problem for Jordan by producing a guideline as a pilot in which the strengths.
Thai Contracting Case Siripen Supakankunti Chantal Herberholz Faculty of Economics.
Abstract ID: 395 Author Name: Araya Sripairoj Presenter Name: Araya Sripairoj Authors: Sripairoj A, Liamputtong P, Harvey K.
P.A. Vorobyev RSPOR president Economy of Equity and Clinico-economic Analysis of Drug Supply in Russian Federation.
Medicines Transparency Alliance15/11/ MEDICINES AVAILABILITY - PHILIPPINES Alexander A. Padilla Undersecretary of Health Vice Chairman, MeTA Philippines.
A BASELINE SURVEY OF THE PHARMACEUTICAL SECTOR IN TANZANIA
Abstract Impact of the Essential Drugs Programme at the Primary Health Care Level in South Africa Hela M, Zeeman H, Department of Health South Africa;
INCREASING HERBAL PRODUCT CONSUMPTION IN THAILAND DURING THE PERIOD Assoc Prof Dr Arthorn Riewpaiboon Department of Pharmaceutical Botany Faculty.
COMPARATIVE ANALYSIS OF SELECTED ESSENTIAL DRUG LISTS AZIZ JAFAROV/RICHARD LAING.
International Health Policy Program -Thailand IHPP : International Health Policy Program, Thailand 12 March 2013 Thai National Health Accounts: sustainable.
Evidence-based priority setting for the National Health Development Plan of Thailand Walaiporn Patcharanarumol, Kanitta Bundhamcharoen, Phusit Prakongsai,
15 March Managing the Dynamics of Drug Supply, Demand, and Health Services Utilization A New Multi-Purpose Tool for Forecasting Drug Requirements.
On the Health of the US Health Care System… Insights and analyses from the National Health Care Survey Irma E. Arispe, PhD Division of Health Care Statistics.
Summary Pattern of Specific COX II Inhibitors Use Physician prescribed appropriate COX II use in high risk was 40.08% and inappropriate COX II use in low.
Authors: Lates JA, Shiyandja NN Funding Institution: Ministry of Health and Social Services, Namibia Title: Third National Survey on the Use of Drugs in.
MONITORING MEDICINE AVAILABILITY AND PRICES IN UGANDA By Denis Kibira HEPS Uganda.
WHO PRESCRIBING INDICATORS (1991 – 1995) TRENDS AND PERSPECTIVES IN AN OUTPATIENT HEALTH CARE FACILITY IN BENIN CITY, NIGERIA. 1 Isah AO, 2 Isah EC, 3.
Indicators for monitoring and assessing pharmaceutical situation in countries Dr. Edelisa D. Carandang Drug Action Program (DAP) Essential Drugs and Medicines.
The Effects of Managerial Intervention on Drug Prescribing Patterns at King Chulalongkorn Memorial Hospital Limpanathikul W, Wangsaturaka D, Nantawan P,
Rapid Penetration of COX2 Inhibitors in Non-Steroidal Antiinflammatory Drug Market: an Implication to Hospital Cost Containment Policy Supon Limwattananon,
1 Outline  Introduction  Methodology for compiling CPI  Data Collection and Compilation.
Impacts of Direct Fee-For- Service Payment Insurance on Access and Use of Drug: An Interrupted Time Series Study on Diabetic Care Inthira Kanchanaphibool,
IMPACT OF TRAINING IN RESPIRATORY GUIDELINES ON IMPROVING USE OF DRUGS Naveen Shrestha Department of Community Medicine and Family Health, IoM, Nepal Louis.
CRVS STRATEGY IN THAILAND Sanchai Techanimitvat Cirawan Matuam Third Regional workshop on Production and Use of Vital Statistics May 26–30, 2014, Daejeon,
Accessibility to Inhaled Cortico-steroids among Adults with Chronic Asthma: AN IMPACT OF THE UNIVERSAL HEALTH CARE COVERAGE POLICY Chulaporn Limwattananon,
IMPROVING ECONOMIC PRESCRIBING IN A TEACHING HOSPITAL THROUGH AN EDUCATIONAL STRATEGY TO PROMOTE GENERIC PRESCRIBING.
MONITORING THE PHARMACEUTICAL SECTOR IN A DEVELOPING COUNTRY - THE GHANA EXAMPLE Gyansa-Lutterodt M. 1,7, Andrews E 2, Arhinful D 3,7, Addo-Atuah J 4,7,
DOES DRUG USE EVALUATION (DUE) REQUIRED BY NATIONAL POLICY IMPROVE USE OF MEDICINES?
Learning About Drug Use1 An Overview of the Process of Changing Drug Use 1. EXAMINE Measure Existing Practices (Descriptive Quantitative Studies) 2. DIAGNOSE.
Does Drug Use Evaluation Required by National Policy Improve Use of Medicines? Akaleephan C*, Muenpa R**, Sittitanyakit B***, Treesak C #, Cheawchanwattana.
Quality Assurance of Medicines under Universal Health Coverage Program by Siriwat Tiptaradol (Presenter) Duangporn Abhigantaphand Sooksri Ungboriboonpisal.
MEDIUM TERM FINANCIAL PLAN ( ) Date : 8/10/2010 Decision No : 2010/28.
Government of Mongolia Government Financial Management and Information System (GFMIS) FreeBalance Case Study ICGFM, April 2004.
International Conference on Improving Use of Medicines
Implementing the guideline
BULGARIA Istanbul, February, Turkey
IMPACT OF DRUG POLICY ON IMPROVING ACCESS TO MEDICINES IN DELHI
Evaluating Sepsis Guidelines and Patient Outcomes
Technology & Healthcare in the Middle East
Drug database and performance indicators for utilization monitoring
Abstract Impact of the National Healthcare Reform on Prescribing Patterns of Promotional Targeted Drugs among Thai Physicians Layton MR*, Chadbunchachai.
BMC Health Service Research 2015 By Gang Nathan Dong PERFORMING WELL IN FINANCIAL MANAGMGMENG AND QUALITY OF CARE.
Abstract No. 452.
A LONGITUDINAL POLICY ANALYSIS OF THE IMPACT ON PRESCRIBING PATTERNS AND MEDICATION COST OF A GENERIC DISPENSING POLICY IN A TEACHING HOSPITAL IN THAILAND.
Presentation transcript:

1 DRUG DATABASE AND PERFORMANCE INDICATORS FOR UTILIZATION MONITORING Authors: Pongcharoensuk P 1, Angsanant M 2, Chantrakunopars P 2, Phuthong P 1, Kongsawat S 1 Institution: 1 Mahidol University; 2 Ministry of Public Health, Thailand Problem Statement: Drug expenditure accounts for 30% of health resources in Thailand. For health care administrators, a standard drug database and management system are essential for utilization monitoring at both national and facility levels. Objective: To determine key performance indicators for drug utilization monitoring. Design: Retrospective, time-series design. Study Population: Twenty-six government hospitals (size range, 10–1,000 beds) with complete electronic drug purchasing database for fiscal years 2000–2002, were purposively selected. Intervention: Different drug codes (of similar drug products) from different hospitals were transformed into the same standard drug code. Using the standardized drug codes, drug purchase data from all 26 hospitals were consolidated to develop key performance indicators. Outcome Measures: Total drug purchase (in baht), ratio of essential drugs (EDs) to nonessential drugs (NEDs), and drug purchase by pharmacological group were used to monitor utilization trends. Unit price statistics of generically equivalent drug products in 2002 were used as indicators for price monitoring of individual product. Results: More than 100,000 drug purchase transactions were gathered. Results showed an increase in total drug purchase from million baht in 2000, to million baht in 2001, and million baht in 2002 (11.0% growth in 2001 and 7.7% in 2002). Also increased was the ratio of NEDs to EDs—15:85 in 2000, 17:83 in 2001, and 18:82 in For pharmacological classification, anti-infectives ranked first in total purchases for all three years but with a decreasing percentage, from 30.0% in 2000, to 26.4% in 2001, and 23.6% in Cardiovascular drugs ranked second in total purchases but with an increasing percentage, from 11.4% in 2000, to 12.4% in 2001, and 13.7% in In unit drug price (baht) statistics for 2002 (listed in the following order: number, average, standard deviation, minimum, maximum, p50, p75, p90), a wide variation was found among both multisource and single-source drugs as follows: aledronate 10 mg tab—48, 48.99, 6.78, 45.86, 81.68, 48.15, 48.15, 48.15; ceftriaxone 1 g inj—22, 36.62, 22.74, 20.18, , 31.03, 37.98, 56.15; and simvastatin 10 mg tab—66, 4.72, 1.92, 2.00, 8.92, 4.24, 5.35, Conclusion: Although not standardized, the drug database available in Thai hospitals can be a valuable resource for utilization monitoring and system management to increase efficiency and effectiveness.

2 Introduction Drugs accounts for 30% of health expenditures in Thailand. Public hospitals are major health service providers including pharmaceutical services. In each hospital, drug database (such as purchase and utilization records) has been kept accumulating for many years. However, these drug databases have limited utility for national policy-making due to the lack of standard structure and code as well as inadequate information technology in data management. Hospital and health care administrators need to use these available data as monitoring tools for decision making and management at both national and facility levels.

3 Objective To determine key performance indicators for drug utilization monitoring: 1. Trend monitoring –Total purchase, ratio ED:NED –Total purchase by drug group, etc. 2. Price monitoring –Unit price* statistics (mean, standard deviation, min, max, percentile 50, 75, 90, 95) of generically equivalent drug products. * Unit price is net purchase price per unit (tablet, bottle).

4 Methodology Study design: retrospective, time-series design. Study Procedure I. Construction of Standard Drug Code (25 digits) –Type (Single* or combinations), 1 digit –Drug Name, Paracetamol, 10 digits –Dosage form, Tablet, 3 digits –Strength, 500 mg., 4 digits –Company, GPO, 4 digits –Package size, 100 tab, 3 digits *Only single chemical entity drug code is available for this study.

5 II. Data collection Sample: 26 public hospitals ( bed) were puposesively selected. They had complete records and were willing to provide a copy of Electronic Drug Purchasing Database of the year III. Data transformation Different drug codes (of the same drug product) from different hospitals are changed into the same standard codes. IV. Data consolidation and analysis All the transformed drug purchasing data from 26 hospitals were consolidated and then analyzed using Microsoft Access, Excel and SQL. Methodology

6 Results: Key performance indicators I. Total drug purchase (million baht) of 26 hospitals in Year Purchase %change (adjusted*) (adjusted*) (898.4) 11.0 (9.9) (947.7) 7.7 (5.6) Notes: *adjusted for inflation of 1.1% in 2001 and 1.9% in 2002 (NESDB).

7 II. Drug Purchase as % of Total Operating Expenses in Type of Hospital (bed) N Range % Avg Regional ( ) General ( ) Community (10-90) (The bigger the hospitals, the more drug used)

8 III. Total Purchase Ratio of Non-Essential Drug (NED) and Essential Drug (ED) Year Ratio (NED:ED) : : :

9 IV. Ranking of Drug Purchase (%) by Pharmacological Groups Rank Group* Anti-bacterials Anti-asthma Anti-diabetics Hypo-lipidemic Anti-anaemic NSAIDS Cytostatic Total (million) *A total of 125 groups

10 V. Unit Purchase Price (baht) Statistics of Generically Equivalent Products of Drug # Min Max Avg p50 p Aledronate 10 mg tab Alprazolam.25 mg tab Atorvastatin 20 mg tab Captopril 25 mg tab Cefoperazone 1 g inj Ceftriaxone 1 g inj Ciprofloxacin 250 mg tab Simvastatin 10 mg tab Rosiglitazone 4 mg tab Notes: Italics are single-source drugs

11 Discussions Lesson learned An urgent need for data management of available hospital database to be utilized for drug system management and policy implementation. Policy implications Structure - A central data warehouse under the Ministry of Public Health, with capability for huge data management. - An agency for determination and maintaining of standard drug codes (possibly FDA?). Process - In addition of Quantity indicators of drug purchase as shown, Quality indicators of drug use are necessary to guarantee good outcomes for the patients and economic outcomes for providers.

12 Conclusions Though not standardized, hospital drug database can be a valuable source for improving system efficiency and effectiveness of drug use. Recommendations More research to be pursued: –Quality of drug use and cost consequences of an illness, particularly chronic diseases such as diabetes or asthma. –Quality of drug use and outcomes of treatment. –Systematic management of drugs (selection, procurement, utilization and outcomes). This study is supported by the National Health Security Office.